Cowen Starts Ocular Therapeutix (OCUL) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
UPDATE: RBC Capital Starts Ocular Therapeutix (OCUL) at Outperform
August 19, 2014 6:46 AM EDT(Updated - August 19, 2014 6:59 AM EDT)
RBC Capital initiated coverage on Ocular Therapeutix (NASDAQ: OCUL) with an Outperform rating and a price target of $21.00.
Analyst Adnan Butt said, "We believe OCUL shares offer the potential for upside as the hydrogel, sustained technology platform... More
Oppenheimer Starts Ocular Therapeutix (OCUL) at Outperform
August 19, 2014 6:46 AM EDTOppenheimer initiated coverage on Ocular Therapeutix (NASDAQ: OCUL) with an Outperform rating and a price target of $25.00.
For an analyst ratings summary and ratings history on Ocular Therapeutix click here. For more ratings news on Ocular Therapeutix click here.
Shares of Ocular Therapeutix closed at $14.33 yesterday.
... More